The award recognises and honors trailblazers who have brought significant impact and business gains for their company’s operations.
Dr. Lai has led ACT Genomics Singapore's Southeast Asia market penetration, sustainable growth, and capacity building. ACT aims to place Singapore on the world map for cancer diagnostics. It looks to develop total solutions for cancer precision management in Singapore that is on demand and improve treatment outcomes by providing more actionable therapeutic options. The business grew more than 10 times and has attracted global investors in its fundraising rounds.
According to Dr. Lai, ACT Genomics Singapore’s cancer diagnostics platform was listed in more than 100 hospitals in Southeast Asia within two years. The company’s revenue has grown substantially to more than 10 times.
“This award affirms the business direction and business model that ACT Genomics Singapore leads. With new markets opening up later this year and next year, we expect a strong growth in our business across emerging markets. We are honored to be recognized in Singapore for spearheading cutting edge molecular diagnostics and benefit more cancer patients at local and from the region,” Dr. Lai said.
Apart from cancer diagnostics services, ACT Genomics Singapore also facilitated the launch of Thailand’s first molecular tumor board at Horizon Cancer Centre, Bumrungrad International Hospital. Employing a multi-disciplinary modality in cancer treatment, the tumour board allows cancer specialists to advance their knowledge and adoption of cancer profiling technology, in turn benefitting cancer patients in their cancer survival.
“The information provided by ACT Genomics is comprehensive yet concise allowing easy interpretation,” Sunway Medical Centre medical oncologist Dr. Tho Lye Mun said, who has utilised the firm’s NGS-based genomic profiling services for his patient. “With the excellent services from ACT Genomics, I trust they will be the choice of NGS Genomics testing service provider that oncologists will engage.”
Dr. Lai’s efforts at ACT Genomics Singapore has also led him to receive the leadership award by Frost & Sullivan for molecular diagnostics product line strategy in Asia Pacific 2017. He has also been invited to speak in several plenary sessions, including the Annual Oncology Conferences, Continuous Medical Education (CME) sessions, Financial Times Healthcare Summit 2017, and Medical Technology Asia Pacific Convention 2017.
The Singapore Business Review Management Excellence Awards was held on November 22, 2018 at the Conrad Centennial Singapore. The award honours the country's most outstanding business leaders, including trailblazing individuals and teams whose initiatives have brought tangible business gains for their company's operations.
The 2018 nominees were judged by a panel consisting of Henry Tan, Managing Director at NEXIA TS; David Chew, Executive Director, Risk Advisory Deloitte Southeast Asia, Lim Wei Wei, Partner, Practice Leader, Governance, and Risk at Baker Tilly TFW; Pardeep Singh Khosa, Director of Dispute Resolution at Drew & Napier; and Yang Eu Jin, Partner and Co Head of Capital Markets Practice at RHTLaw Taylor Wessing LLP.
If you would like to join the 2019 awards and be awarded as one of the most outstanding management executives of Singapore, please email email@example.com.
Do you know more about this story? Contact us anonymously through this link.